Mumbai-based pharma maker of branded/generic formulations and APIs, exporting to 100+ countries.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 |
| Reserves | 3.7k | 4.7k | 5.5k | 5.9k | 6.3k | 6.9k | 7.4k | 8.0k |
| Borrowings | 474 | 236 | 776 | 1.4k | 1.2k | 906 | 1.3k | 295 |
| Other Liabilities | 1.0k | 1.0k | 1.2k | 1.1k | 1.2k | 1.3k | 3.6k | 1.5k |
| Total Liabilities | 5.2k | 6.0k | 7.4k | 8.4k | 8.7k | 9.1k | 12.3k | 9.8k |
| AssetsFixed Assets | 1.8k | 1.9k | 2.2k | 2.5k | 2.5k | 2.5k | 4.4k | 3.0k |
| CWIP | 84 | 182 | 297 | 123 | 175 | 490 | 777 | 459 |
| Investments | 649 | 868 | 1.3k | 1.1k | 2.7k | 2.7k | 1.2k | 2.5k |
| Other Assets | 2.6k | 3.1k | 3.6k | 4.8k | 3.3k | 3.4k | 5.9k | 3.8k |
| Total Assets | 5.2k | 6.0k | 7.4k | 8.4k | 8.7k | 9.1k | 12.3k | 9.8k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 496 | 561 | 1.1k | 832 | 762 | 831 | 1.4k | 1.4k |
| Cash from Investing | -123 | -499 | -560 | -812 | -710 | -1.4k | -739 | -697 |
| Cash from Financing | -223 | -139 | -307 | 426 | 506 | -465 | -428 | -745 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 430 | 301 | 749 | 384 | 362 | 474 | 776 | 718 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (49.7×) and current (42.6×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 32.6% growth and a 43× exit, ₹1901 only delivers your return if you pay ₹3,741. The price is currently baking in 17% growth.
EPS grows 32.6%/yr for 5 years, then fades to 6% over 2, exits at 43×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 32.6% | 59.19 |
| FY28 | 32.6% | 78.49 |
| FY29 | 32.6% | 104.08 |
| FY30 | 32.6% | 138.01 |
| FY31 | 32.6% | 183.00 |
| FY32 | 19.3% ·fade | 218.31 |
| FY33 | 6.0% ·fade | 231.41 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.